WO2007047634A3 - Method to diagnose, predict treatment response and develop treatments for psychiatric disorders using markers - Google Patents

Method to diagnose, predict treatment response and develop treatments for psychiatric disorders using markers Download PDF

Info

Publication number
WO2007047634A3
WO2007047634A3 PCT/US2006/040475 US2006040475W WO2007047634A3 WO 2007047634 A3 WO2007047634 A3 WO 2007047634A3 US 2006040475 W US2006040475 W US 2006040475W WO 2007047634 A3 WO2007047634 A3 WO 2007047634A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnose
markers
psychiatric disorders
treatment response
predict treatment
Prior art date
Application number
PCT/US2006/040475
Other languages
French (fr)
Other versions
WO2007047634A2 (en
Inventor
John R Kelsoe
Sherri Liang
Xianjin Zhou
Original Assignee
Univ California
John R Kelsoe
Sherri Liang
Xianjin Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, John R Kelsoe, Sherri Liang, Xianjin Zhou filed Critical Univ California
Priority to US11/992,835 priority Critical patent/US20100222415A1/en
Publication of WO2007047634A2 publication Critical patent/WO2007047634A2/en
Publication of WO2007047634A3 publication Critical patent/WO2007047634A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The disclosure provides methods and compositions useful for identifying a subject's predisposition or diagnosis of a mental disorder, methods of screening for agents useful for treating such a disorder and methods of treatment thereof .
PCT/US2006/040475 2005-10-14 2006-10-13 Method to diagnose, predict treatment response and develop treatments for psychiatric disorders using markers WO2007047634A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/992,835 US20100222415A1 (en) 2005-10-14 2006-10-13 Method to Diagnose, Predict Treatment Response and Develop Treatment for Psychiatric Disorders Using Markers

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72697805P 2005-10-14 2005-10-14
US60/726,978 2005-10-14
US74966805P 2005-12-09 2005-12-09
US60/749,668 2005-12-09

Publications (2)

Publication Number Publication Date
WO2007047634A2 WO2007047634A2 (en) 2007-04-26
WO2007047634A3 true WO2007047634A3 (en) 2009-04-30

Family

ID=37963194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040475 WO2007047634A2 (en) 2005-10-14 2006-10-13 Method to diagnose, predict treatment response and develop treatments for psychiatric disorders using markers

Country Status (2)

Country Link
US (1) US20100222415A1 (en)
WO (1) WO2007047634A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100233702A1 (en) * 2007-10-04 2010-09-16 The Regents Of The University Of California Method to predict response to treatment for psychiatric illnesses
WO2009101619A2 (en) * 2008-02-11 2009-08-20 Ramot At Tel-Aviv University Ltd. Methods for predicting a patient's response to lithium treatment
EP2682751A1 (en) * 2012-07-04 2014-01-08 Parc Sanitari Sant Joan de Déu Method for diagnosing psychiatric disorders in a human subject assessing the concentration of SP1, SP3 and SP4 proteins in a biological sample
CN103773882A (en) * 2014-02-07 2014-05-07 上海市长宁区精神卫生中心 Application of substances for detecting rs40245 site nucleotide in early evaluation of risk of schizophrenia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166519A1 (en) * 2002-12-20 2004-08-26 Applera Corporation Genetic polymorphisms associated with stenosis, methods of detection and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
WO1995011995A1 (en) * 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US20020077756A1 (en) * 1999-11-29 2002-06-20 Scott Arouh Neural-network-based identification, and application, of genomic information practically relevant to diverse biological and sociological problems, including drug dosage estimation
CA2414403A1 (en) * 2000-07-06 2002-01-17 The Regents Of The University Of California Methods for diagnosis and treatment of psychiatric disorders
EP1423535A4 (en) * 2001-08-04 2005-07-06 Whitehead Biomedical Inst Haplotype map of the human genome and uses therefor
US20040210400A1 (en) * 2003-01-27 2004-10-21 Perlegen Sciences, Inc. Analysis methods for individual genotyping
US20050069936A1 (en) * 2003-09-26 2005-03-31 Cornelius Diamond Diagnostic markers of depression treatment and methods of use thereof
US20050176057A1 (en) * 2003-09-26 2005-08-11 Troy Bremer Diagnostic markers of mood disorders and methods of use thereof
US20060129324A1 (en) * 2004-12-15 2006-06-15 Biogenesys, Inc. Use of quantitative EEG (QEEG) alone and/or other imaging technology and/or in combination with genomics and/or proteomics and/or biochemical analysis and/or other diagnostic modalities, and CART and/or AI and/or statistical and/or other mathematical analysis methods for improved medical and other diagnosis, psychiatric and other disease treatment, and also for veracity verification and/or lie detection applications.
WO2006083854A2 (en) * 2005-01-31 2006-08-10 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
US7906281B2 (en) * 2005-10-07 2011-03-15 The Regents Of The University Of California Method to predict the response to lithium treatment
US20100233702A1 (en) * 2007-10-04 2010-09-16 The Regents Of The University Of California Method to predict response to treatment for psychiatric illnesses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166519A1 (en) * 2002-12-20 2004-08-26 Applera Corporation Genetic polymorphisms associated with stenosis, methods of detection and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
db SNP rs12673091, ss20322985, submitted 21 Feb 2004 pages 1-4 *
db SNP rs48202391, ss24140240, submitted 10 Augustus 2004 pages 1-4 *
FAN J.-B.: "PARALLEL GENOTYPING OF HUMAN SNPS USING GENERIC HIGH-DENSITY OLIGONUCLEOTIDE TAG ARRAYS", GENOME RESEARCH, vol. 10, no. 6, 1 June 2000 (2000-06-01), pages 853 - 860, XP002934219 *
LETTS V.A. ET AL.: "THE MOUSE STARGAZER GENE ENCODES A NEURONAL CA2+-CHANNEL GAMMA SUBUNIT", NATURE GENETICS, vol. 19, no. 4, 1 August 1998 (1998-08-01), pages 340 - 347, XP000857265 *

Also Published As

Publication number Publication date
WO2007047634A2 (en) 2007-04-26
US20100222415A1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
WO2008021210A3 (en) Methods and compositions for the treatment of neurodegenerative disorders
HK1069767A1 (en) Methods for inhibiting ocular processes
WO2007101190A3 (en) Clinical applications of sto2 analysis
WO2007041697A3 (en) Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
EP1680009A4 (en) Compositions and methods for diagnosing and treating mental disorders
WO2008070137A3 (en) Interferon alpha-induced pharmacodynamic markers
WO2006083986A3 (en) Biomarkers for tissue status
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
WO2003007803A3 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
WO2005060520A3 (en) ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2007044695A3 (en) ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2008137838A3 (en) Interferon alpha-induced pharmacodynamic markers
WO2006034296A3 (en) Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
WO2006119775A3 (en) Method for diagnosis and treatment, of a mental disease
WO2007089715A3 (en) Method for treatment of neuropathic pain
WO2010059242A3 (en) Neurodegenerative disease diagnostic compositions and methods of use
PL378587A1 (en) Methods of (S)-(-)-2-amino-6-n-propyloamino-4,5,6,7-tetrahydrobenzotiazole and/or its salts
WO2006080549A3 (en) Method and composition for treating central nervous system disorders
BRPI0508084A (en) method for the treatment of a neurological disorder, and use of meridamycin or a salt thereof
WO2007047634A3 (en) Method to diagnose, predict treatment response and develop treatments for psychiatric disorders using markers
WO2004107958A3 (en) Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
EP1254260A4 (en) Methods for diagnosing and treating heart disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11992835

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06836339

Country of ref document: EP

Kind code of ref document: A2